Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease
Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease
复制标题
DOI：
10.1586/eci.09.70
复制
发表时间：
2010-01-01
影响因子：
4.4
通讯作者：
Guandalini, Stefano
中科院分区：
文献类型：
--
作者：
Guandalini, Stefano
在过去的几年里，益生菌已经有了许多应用，胃肠道的炎症性疾病-包括慢性疾病，如炎症性肠病（IBD）-受到了研究人员的最大关注。事实上，预期益生菌在IBD中的临床疗效的实验基础是相当稳健的。然而，尽管如此，目前在克罗恩病中，无论是在成人还是在儿科人群中，只有最少的证据表明任何益生菌的益处。另一方面，在溃疡性结肠炎中，已发现几种益生菌制剂，尤其是专利制剂VSL#3（一种高浓度混合物）可有效作为辅助治疗，诱导和维持缓解。
Probiotics have had many applications in the past few years, and inflammatory conditions of the GI tract - including chronic disorders such as inflammatory bowel disease (IBD) - have received the most attention by investigators. In fact, the experimental basis to expect clinical efficacy of probiotics in IBD is quite robust. In spite of this however, only minimal evidence of benefit by any probiotic is currently available in Crohn's disease, either in adult or in pediatric populations. In ulcerative colitis, on the other hand, several probiotic formulations and especially the proprietary preparation VSL#3 (a high-concentration mixture) have been found effective as adjuvant therapy, both in inducing and maintaining remission.